Scientific job: CLAIMED. Generic nuclear imaging remains inside the existing Radiology & Imaging Web. This article owns the narrower theranostic movement from molecular/physiological target → radiopharmaceutical → PET/SPECT or other nuclear distribution evidence → target expression/functional interpretation → treatment eligibility → patient-specific activity/dosimetry where relevant → targeted radionuclide therapy → toxicity/response monitoring → repeat molecular assessment.

Wait, what? The same biological target can sometimes be used first to see disease—and then to treat it.

This is the core idea of theranostics. A molecule is chosen because it binds to or participates in a biological process of interest. Attach an imaging radionuclide and its distribution can reveal where that target is active. In selected diseases, a related targeting molecule can carry therapeutic radiation to the same target.

The job is therefore larger than “take a scan”. The useful loop is target → image → eligibility → therapy → response → image again.

The theranostic tube

Clinical question → biological target → radiopharmaceutical selection → patient preparation → administration → PET/SPECT/planar distribution → quantitative/qualitative interpretation → treatment eligibility → dosimetry/activity planning where needed → radionuclide therapy → radiation-safety precautions → blood/organ/tumour response monitoring → repeat imaging → continue, adapt or stop.

1. Radiopharmaceuticals are medicines and measurement tools

A radiopharmaceutical combines a radioactive isotope with a molecule that follows a biological pathway or binds a target. SingHealth describes nuclear medicine as using radioactive isotopes for both diagnosis and treatment. That dual role is what makes the object distinctive.

For eduKateAI, the radiopharmaceutical should preserve identity, radionuclide, biological target, purpose, administered activity, date/time, route, production/quality context where relevant and whether the use is diagnostic or therapeutic.

2. PET and SPECT image biology rather than anatomy alone

Nuclear medicine images the distribution of radioactive tracers in the body. PET and SPECT can reveal metabolism, perfusion, receptor expression, bone turnover or other biological processes depending on the tracer.

That complements CT and MRI rather than replacing them. Structural imaging answers where anatomy has changed; molecular imaging can show biological activity before, alongside or after structural change.

3. Target expression can become an eligibility gate

Some targeted radionuclide therapies work only when the relevant target is sufficiently present. SingHealth’s PRRT pathway, for example, uses a receptor-targeted PET/CT scan before treatment to determine whether a neuroendocrine tumour expresses the appropriate somatostatin receptors.

This creates a strong routing rule: diagnosis present ≠ target present enough for theranostic treatment. Disease identity and therapeutic target expression are different clinical objects.

4. Dosimetry turns radiation into a patient-specific state

Radiopharmaceutical therapy is not simply “give radioactive medicine”. The amount of energy absorbed by tumours and normal organs can matter to benefit and toxicity. The IAEA’s 2026 medical-radiation-dosimetry programme explicitly covers patient-specific and imaging-based dosimetry, quantitative radionuclide imaging, pharmacokinetic modelling and theranostic PET/CT and SPECT/CT.

For eduKateAI: administered activity ≠ absorbed dose. The activity put into the patient and the radiation dose ultimately absorbed by a particular tissue are related but not identical quantities.

5. Theranostics crosses Imaging, Pharmacy, Oncology and Medical Physics

Radiology/Nuclear Medicine owns image acquisition and interpretation. Pharmacy and radiopharmacy own medicine-product quality and safe handling. Oncology owns the cancer trajectory. Medical Physics supports quantitative imaging, dosimetry and radiation protection. Nursing and other teams support administration, monitoring and patient education.

The theranostic node does not absorb these owners; it exists to preserve the targeted loop connecting them.

6. PRRT demonstrates the complete loop

Peptide receptor radionuclide therapy targets somatostatin receptors expressed by selected neuroendocrine tumours. SingHealth describes a pathway in which receptor imaging helps establish suitability, therapeutic radiopharmaceutical is administered intravenously, post-treatment imaging checks distribution and blood, kidney and liver function are monitored.

This is a canonical eduKateAI tube: molecular target verified → therapy delivered → where the therapy went is observed → organ and tumour receipts return.

7. PSMA therapy shows the same architecture with a different target

Selected prostate cancers can express prostate-specific membrane antigen strongly enough to become targets for imaging and radioligand therapy. SingHealth currently provides Lu-177 PSMA therapy and follows patients with imaging and serial blood tests after treatment.

Urology owns prostate anatomy and urological care; Oncology owns systemic cancer trajectory; Nuclear Medicine & Theranostics owns the target-imaging-radioligand-treatment loop.

8. Response is multi-dimensional

Tumour size, molecular uptake, biochemical markers, symptoms, blood counts, kidney/liver function and patient wellbeing may change differently. A falling marker or changing scan is useful evidence, but no single measure automatically represents the whole outcome.

The Oncology Web integrates disease response; the theranostic node preserves what the targeted radiopharmaceutical did and whether the biological target remains useful.

9. Radiation safety continues after administration

Some therapeutic radionuclides remain in the body long enough that patients may need temporary precautions around close contact, bodily fluids or particular vulnerable groups. Requirements differ by radionuclide, treatment, dose and local regulation.

For eduKateAI, radiation-safety instructions must always remain therapy-specific, jurisdiction-specific and time-limited; they should never be generalised from one radionuclide to another.

10. The loop can repeat

Some radionuclide therapies are delivered over several cycles. Eligibility can be reassessed between cycles using blood counts, organ function, symptoms, imaging and disease response. The treatment plan therefore recompiles after each receipt.

This is a strong fit for eduKateAI’s longitudinal machinery: measure → treat → observe → update state → decide again.

Characteristic failure modes

• Nuclear medicine = ordinary scan error: therapy and target-selection functions disappear.
• Diagnosis = target error: disease label treated as proof that the therapeutic target is sufficiently expressed.
• Activity = dose error: administered radioactivity confused with tissue absorbed dose.
• Image-only error: molecular uptake interpreted without clinical, pathology and treatment context.
• Therapy-complete error: administration treated as endpoint without toxicity, distribution and response receipts.
• Safety-generalisation error: radiation precautions copied between different radionuclides or jurisdictions.

The eduKateAI routing contract

• Canonical public owner: Nuclear Medicine & Theranostics Web.
• Input state: molecular-imaging question, target-expression question or targeted radionuclide-therapy pathway.
• Primary job: preserve target, radiopharmaceutical, quantitative imaging, dosimetry, therapeutic administration and response as one closed loop.
• Do not collapse: diagnosis ≠ target expression; administered activity ≠ absorbed dose; scan result ≠ treatment eligibility by itself.
• Handoffs: Radiology/Imaging, Oncology, Pharmacy/Radiopharmacy, Medical Physics, Laboratory Medicine, Pathology, Urology, Endocrine Medicine and relevant organ specialties.
• Return receipt: target demonstrated/not demonstrated, therapy eligible/not eligible, dose/activity documented, distribution acceptable, toxicity acceptable/unacceptable, response observed, next cycle continued/modified/stopped.

Authoritative routes

• IAEA — Nuclear Medicine and Radiation Protection
• IAEA — IDOS 2026: nuclear medicine, radiopharmaceutical therapy and theranostic dosimetry
• SingHealth — Nuclear Medicine
• SingHealth — Peptide Receptor Radionuclide Therapy
• SingHealth — Lu-177 PSMA Radionuclide Therapy

Educational boundary: this article explains nuclear-medicine and theranostic information architecture. It does not determine treatment eligibility, calculate administered activity or dosimetry, interpret an individual PET/SPECT study or provide radiation-safety instructions for a real patient.